What is a low-cost TB diagnostic kit business in India?

It is manufacturing or distributing simple, affordable TB test kits (using tongue or nasal swabs) to government health centers, private clinics, and rural areas. India has 25 million TB cases yearly, and most deaths occur within 2 weeks because testing is slow and expensive in villages. A ₹50-60 kit can be sold at ₹80-120 to clinics, generating ₹20-30 margin per unit.

How much does it cost to start this business in India?

₹40-60 lakh for full setup (manufacturing/sourcing, CDSCO approval, inventory, distribution). Breakdown: Contract manufacturing setup ₹25 lakh, regulatory approvals ₹10 lakh, working capital and distribution ₹15 lakh, marketing ₹5 lakh. Can start with ₹15-20 lakh using contract manufacturers without owning a facility.

Is this business profitable in India?

Yes. At ₹50-60 manufacturing cost and ₹80-120 selling price, profit per kit is ₹20-30. If you sell 500,000 kits in year 1, profit is ₹1-1.5 crore. Government TB programs alone test 5-6 million patients yearly, creating consistent bulk orders. Rural and private markets are growing 15-20% annually as TB screening expands.

What regulations apply to this business in India?

CDSCO (Central Drugs Standards Control Organisation) approval is mandatory as the kits are classified as in-vitro diagnostic devices under the Drugs and Cosmetics Act, 1940. Process takes 4-6 months and costs ₹8-15 lakh. ISO 13485:2016 quality certification is recommended (₹3-5 lakh). GST is 5% on diagnostic kits. Each state's drugs controller also requires approval. Government procurement requires GeM portal registration and tender participation.

TB Testing Kit Business India 2026 — Startup Guide

AI SummaryA low-cost TB diagnostic kit business targets India's 3,00,000 annual TB deaths—a curable disease killing patients within 2 weeks of diagnosis due to slow/expensive testing. The market is worth ₹2,000-3,000 crore annually across government TB programs (5-6M tests/year), private clinics, and underserved rural/tribal areas where TB rates are 50% higher than urban regions. Timing is right in 2026 because (1) government is scaling TB screening under NIKSHAY, (2) WHO and India's National TB Elimination Plan demand faster diagnostics, and (3) the ₹80 cost reduction cited in the article creates margin opportunity. Entrepreneurs with ₹40-60 lakh, manufacturing/sourcing networks, and regulatory compliance ability should pursue this.